Compare · ATHA vs BIIB
ATHA vs BIIB
Side-by-side comparison of Athira Pharma Inc. (ATHA) and Biogen Inc. (BIIB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ATHA and BIIB operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BIIB is the larger of the two at $27.94B, about 74.8x ATHA ($373.5M).
- Over the past year, ATHA is up 135.2% and BIIB is up 56.6% - ATHA leads by 78.6 points.
- BIIB has hit the wire 14 times in the past 4 weeks while ATHA has been quiet.
- BIIB has more recent analyst coverage (25 ratings vs 13 for ATHA).
- Company
- Athira Pharma Inc.
- Biogen Inc.
- Price
- $6.87-1.43%
- $189.40-2.59%
- Market cap
- $373.5M
- $27.94B
- 1M return
- +71.32%
- +3.29%
- 1Y return
- +135.19%
- +56.59%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 0
- 14
- Recent ratings
- 13
- 25
Athira Pharma Inc.
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and stop neurodegradation. Its lead product candidate is ATH-1017, a blood brain barrier-penetrating, small hepatocyte growth factor/MET activator that is in LIFT-AD Phase II/III and ACT-AD Phase II clinical trials for the treatment of mild-to-moderate Alzheimer's disease, as well as in clinical development for Parkinson's disease. The company also develops product candidates, which are in preclinical stage, including ATH-1019/ATH-1020 for neuropsychiatric conditions; and ATH-1018 for peripheral nervous system disorders, such as neuropathy. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.
Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Latest ATHA
- Amendment: SEC Form SCHEDULE 13D/A filed by Athira Pharma Inc.
- Athira Pharma Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Leadership Update, Financial Statements and Exhibits
- Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker "LONA"
- CHIEF MEDICAL OFFICER San Martin Javier converted options into 4,667 shares and sold $11,311 worth of shares (1,644 units at $6.88), increasing direct ownership by 42% to 10,189 units (SEC Form 4)
- President and CEO Litton Mark James sold $17,792 worth of shares (2,586 units at $6.88) and converted options into 10,834 shares, increasing direct ownership by 25% to 40,828 units (SEC Form 4)
- Chief Financial Officer Renninger Robert was granted 1,000 shares, converted options into 1,236 shares and sold $2,043 worth of shares (297 units at $6.88), increasing direct ownership by 18% to 12,857 units (SEC Form 4)
- CHIEF SCIENTIFIC OFFICER Church Kevin was granted 1,000 shares, converted options into 3,667 shares and sold $6,027 worth of shares (876 units at $6.88), increasing direct ownership by 22% to 20,681 units (SEC Form 4)
- General Counsel and CCO Worthington Mark converted options into 3,667 shares and sold $6,027 worth of shares (876 units at $6.88), increasing direct ownership by 25% to 13,978 units (SEC Form 4)
- SEC Form 4 filed by Chief Financial Officer Renninger Robert
- SEC Form 4 filed by President and CEO Litton Mark James
Latest BIIB
- Stoke Therapeutics to Host Webcast and Conference Call to Discuss First Quarter 2026 Business and Financial Updates
- SEC Form 10-Q filed by Biogen Inc.
- Biogen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form DEFA14A filed by Biogen Inc.
- SEC Form DEF 14A filed by Biogen Inc.
- FDA Approval for ZURZUVAE issued to BIOGEN INC
- Biogen upgraded by UBS with a new price target
- Biogen upgraded by Wells Fargo with a new price target
- TJ Biopharma Enters into Agreement with Biogen for Felzartamab Assets in the Greater China Region
- Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region